{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T22:12:28Z","timestamp":1716934348820},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.remn.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T15:57:22Z","timestamp":1462636642000},"page":"283-286","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety of regadenoson in patients with severe chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"35","author":[{"given":"C.","family":"Salgado-Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jimenez-Heffernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ramos-Font","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lopez-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sanchez-de-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Aroui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lopez-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rivera-de-los-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ruiz-Frutos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2016.03.005_bib0080","article-title":"Stress protocols and tracers","author":"Henzlova","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12350-012-9565-2","article-title":"Regadenoson stress in patients with asthma and COPD: a breath of fresh air","volume":"19","author":"Thompson","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","article-title":"Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial)","volume":"15","author":"Thomas","year":"2008","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","article-title":"A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease","volume":"19","author":"Prenner","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00259-013-2493-9","article-title":"Comparative study of the safety of regadenoson between patients with mild\/moderate chronic obstructive pulmonary disease and asthma","volume":"41","author":"Salgado-Garcia","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remn.2016.03.005_bib0105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.arbres.2010.06.008","article-title":"Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors","volume":"46","author":"Soriano","year":"2010","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.remn.2016.03.005_bib0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12350-008-9001-9","article-title":"The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging","volume":"16","author":"Thomas","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/clc.4960130905","article-title":"Thallium-201 perfusion imaging with atrial pacing or dipyridamole stress testing for evaluation of cardiac risk prior to nonvascular surgery","volume":"13","author":"Stratmann","year":"1990","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0120","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary","volume":"176","author":"Klaus","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.remn.2016.03.005_bib0125","first-page":"535","article-title":"Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions","volume":"2","author":"Albouaini","year":"2007","journal-title":"Int J Chron Obstr Pulm Dis"},{"key":"10.1016\/j.remn.2016.03.005_bib0130","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.rmed.2008.04.010","article-title":"Underdiagnosis of myocardial infarction in COPD \u2013 Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation","volume":"102","author":"Brekke","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.remn.2016.03.005_bib0135","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s12350-015-0141-4","article-title":"Serious and potentially life threatening complications of cardiac stress testing: physiological mechanisms and management strategies","volume":"22","author":"Dilsizian","year":"2015","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00259-013-2619-0","article-title":"Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy","volume":"41","author":"Brinkert","year":"2014","journal-title":"Eur J Nucl Mol Imaging"},{"key":"10.1016\/j.remn.2016.03.005_bib0145","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12350-010-9229-z","article-title":"Lessons from regadenoson and low-level treadmill\/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients","volume":"17","author":"Kwon","year":"2010","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remn.2016.03.005_bib0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nuclcard.2008.02.009","article-title":"Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Leaker","year":"2008","journal-title":"J Nucl Cardiol"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X16300026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X16300026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T03:26:38Z","timestamp":1536722798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X16300026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2253654X16300026"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2016.03.005","relation":{},"ISSN":["2253-654X"],"issn-type":[{"value":"2253-654X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of regadenoson in patients with severe chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y SEMNIM. All rights reserved.","name":"copyright","label":"Copyright"}]}}